dc.contributor.author |
Spicer, Julie |
en |
dc.contributor.author |
Rewcastle, Gordon |
en |
dc.contributor.author |
Kaufman, MD |
en |
dc.contributor.author |
Black, Shannon |
en |
dc.contributor.author |
Plummer, MS |
en |
dc.contributor.author |
Denny, William |
en |
dc.contributor.author |
Quinn, J |
en |
dc.contributor.author |
Shahripour, AB |
en |
dc.contributor.author |
Barrett, SD |
en |
dc.contributor.author |
Whitehead, CE |
en |
dc.contributor.author |
Milbank, JBJ |
en |
dc.contributor.author |
Ohren, JE |
en |
dc.contributor.author |
Gowan, RC |
en |
dc.contributor.author |
Omer, C |
en |
dc.contributor.author |
Camp, HS |
en |
dc.contributor.author |
Esmaeil, N |
en |
dc.contributor.author |
Moore, K |
en |
dc.contributor.author |
Sebolt-Leopold, JS |
en |
dc.contributor.author |
Pryzbranowski, S |
en |
dc.contributor.author |
Merriman, RL |
en |
dc.contributor.author |
Ortwine, DF |
en |
dc.contributor.author |
Warmus, JS |
en |
dc.contributor.author |
Flamme, CM |
en |
dc.contributor.author |
Pavlovsky, AG |
en |
dc.contributor.author |
Tecle, H |
en |
dc.date.accessioned |
2011-11-17T17:10:32Z |
en |
dc.date.issued |
2007 |
en |
dc.identifier.citation |
Journal of Medicinal Chemistry 50(21):5090-5102 2007 |
en |
dc.identifier.issn |
0022-2623 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/9202 |
en |
dc.description.abstract |
A new series of MEK1 inhibitors, the 4-anilino-5-carboxamido-2-pyridones, were designed and synthesized using a combination of medicinal chem., computational chem., and structural elucidation. The effect of variation in the carboxamide side chain, substitution on the pyridone nitrogen, and replacement of the 4'-iodide were all investigated. This study afforded several compds. which were either equipotent or more potent than the clin. candidate CI-1040 (1) in an isolated enzyme assay, as well as murine colon carcinoma (C26) cells, as measured by suppression of phosphorylated ERK substrate. Most notably, pyridone 27 was found to be more potent than 1 in vitro and produced a 100% response rate at a lower dose than 1, when tested for in vivo efficacy in animals bearing C26 tumors |
en |
dc.language |
EN |
en |
dc.publisher |
American Chemical Society |
en |
dc.relation.ispartofseries |
Journal of Medicinal Chemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from
http://www.sherpa.ac.uk/romeo/issn/0022-2623/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
ORAL MEK INHIBITOR |
en |
dc.subject |
CANCER |
en |
dc.subject |
PATHWAY |
en |
dc.subject |
PROGRESS |
en |
dc.subject |
CASCADE |
en |
dc.subject |
CI-1040 |
en |
dc.subject |
GROWTH |
en |
dc.subject |
POTENT |
en |
dc.subject |
TUMORS |
en |
dc.subject |
COLON |
en |
dc.title |
4-Anilino-5-carboxamido-2-pyridone Derivatives as Noncompetitive Inhibitors of Mitogen-Activated Protein Kinase Kinase |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1021/jm0704548 |
en |
pubs.issue |
21 |
en |
pubs.begin-page |
5090 |
en |
pubs.volume |
50 |
en |
dc.rights.holder |
Copyright: American Chemical Society |
en |
dc.identifier.pmid |
17880056 |
en |
pubs.end-page |
5102 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
72718 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
17880056 |
en |